申请人:Novo Nordisk A/S
公开号:US05646146A1
公开(公告)日:1997-07-08
The present invention relates to 9H-indeno[1,2-b]pyrazin-3(4H)-ones and 9H-indeno[1,2-b]pyrazine-2,3(1H,4H)-diones or tautomeric forms thereof which are useful in treating neurological and psychiatric diseases based on the antagonism of the glycine binding site on the NMDA receptor complex.
本发明涉及9H-吲哚并[1,2-b]吡嗪-3(4H)-酮和9H-吲哚并[1,2-b]吡嗪-2,3(1H,4H)-二酮或其互变异构体,其可用于治疗基于抗NMDA受体复合物上甘氨酸结合位点的神经和精神疾病。